News

AC Immune First Half 2026 Financial and Corporate Update

Focused portfolio of wholly-owned programs approach near-term…

Simris Group Appoints Biotechnology Expert Dr. Tiffany J. Vora as Strategic Advisor

Hammenhög, Sweden, July 28, 2026 — Simris Group AB (SIMRIS…
xeltis

ReBio Pharma appoints leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer

· Brings nearly three decades of clinical, translational and…

Hansa Biopharma Reports Second Quarter and First Half Year 2026 Financial Results

€115 million out-licensing agreement Positive data…

Advanced Medical Solutions Group plc – Half Year 2026 Trading Update

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),…

Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology

Nucleome’s advance in precision and scale of 3D genomics has…

ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board

Ian Wells, former Global Chief Financial Officer of HOYA…

Poolbeg Pharma Plc – Placing to raise £3.5 million, Executive Chair Cathal Friel subscribes for £250,000

Poolbeg Pharma Plc (AIM: POLB), a clinical-stage biopharmaceutical…

Poolbeg Pharma plc – First Patient Dosed in the POLB 001 TOPICAL Clinical Trial

Interim data remains on track for summer 2026 and partnering…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.